Effective against COVID19 this is big!

Medigus: Polyrizon’s innovative proprietary technology found effective against coronavirus in a pre-clinical study

Medigus Ltd

July 23, 2021, 7:48 pm

Polyrizon’s formulations demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells' death

OMER, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Polyrizon’s technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.